- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Approved drug?||Yes (EMA and FDA (2013))|
|International Nonproprietary Names|
|ado-trastuzumab emtansine | Kadcyla® | PRO-132365 | RG-3502|
|Trastuzumab emtansine is a antibody-drug conjugate (ADC) containing a targeting antibody (anti-erbB2) conjugated to a cytotoxic drug (mertansine or DM1) . The PubChem CID for the mertasine component compound is CID 11343137. Mertansine (or DM1) is a macrolide of the ansamycin type and can be isolated from plants of the genus Maytenus. It is known as a maytansinoid. This agent binds to the rhizoxin binding site on β-tubulin and functions in a similar fashion to the Vinca alkaloids.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Other trastuzumab antibody-drug conjugates (ADCs) in development:
trastuzumab duocarmazine (SYD985; Synthon Biopharmaceuticals)  delivers a toxic DNA methylating compound to target cancer cells. It is in Phase 3 development (NCT03262935).
trastuzumab deruxtecan (DS-8201; Daiichi Sankyo) delivers a topoisomerase I inhibitor payload. It is in Phase 3 development (NCT03529110).
|GtoPdb PubChem SID||178103510|
|Search PubMed clinical trials||trastuzumab emtansine|
|Search PubMed titles||trastuzumab emtansine|
|Search PubMed titles/abstracts||trastuzumab emtansine|